Galena Biopharma, Inc. : GALE

GALE

Stock Data

$0.26

$0.01 (5.11%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

All GALE Articles

30 Articles

Paul Ausick | Feb 10, 2017 at 4:04 PM EST

Biostage, Fossil Group Tumble into Friday’s 52-Week Low Club

Biostage, Fossil Group, Galena Biopharma, and Himax posted new 52-week lows on Friday.

Paul Ausick | Feb 8, 2017 at 4:08 PM EST

Gilead Sciences, Fitbit Plunge into Wednesday’s 52-Week Low Club

Gilead Sciences, Gale Biopharma, Teva, and Fitbit post new 52-week lows Wednesday.

Chris Lange | Feb 8, 2017 at 11:35 AM EST

Wednesday’s Biggest Biopharma Movers

Not that many biotech and pharma companies were on the move Wednesday, but a few of the smaller caps made…

Paul Ausick | Jan 9, 2017 at 4:04 PM EST

DryShips, Stage Stores Plunge into Monday’s 52-Week Low Club

DryShips, Stage Stores, Galena Biopharma, and Diplomat Pharmacy post new 52-week lows on Monday.

Chris Lange | Dec 28, 2016 at 3:43 PM EST

Galena Rises on FDA Approval

Galena Biopharma, Inc. (NASDAQ: GALE) saw its shares jump on Wednesday after a key U.S. Food and Drug Administration (FDA)…

Chris Lange | Oct 6, 2016 at 8:35 AM EDT

7 Key FDA Decisions and Clinical Trial Results Coming in Q4

24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in…

Chris Lange | Jul 3, 2016 at 9:35 AM EDT

4 Companies That Destroyed Shareholders Despite a Brexit Recovery

Despite Brexit absolutely rocking the market over a week ago, the broad markets made a solid comeback leading most people to…

Chris Lange | Jun 29, 2016 at 1:21 PM EDT

Is Galena Dead in the Water After This Failed Trial?

Galena Biopharma, Inc. (NASDAQ: GALE) is absolutely crashing on Wednesday after the company released further information regarding its Breast Cancer…

Chris Lange | Mar 29, 2016 at 9:35 AM EDT

8 Major Biopharma Events Coming Later in 2016 and in 2017

FDA rulings can make or break some companies. 24/7 Wall St. has collected eight key FDA decisions coming up in…

Jon C. Ogg | Feb 21, 2014 at 8:05 AM EST

Top Wall Street Analyst Sell Ratings on High Profile Stocks This Week

ThinkstockAt 24/7 Wall Street we have been running weekly research screens to scan the brokerage firms we cover for the…

Jon C. Ogg | Feb 18, 2014 at 8:30 AM EST

Top Analyst Upgrades and Downgrades: BlackBerry, Care.com, Lululemon, Tesla, Veeco and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Tuesday February 18, 2014.…

Jon C. Ogg | Feb 7, 2014 at 8:15 AM EST

Eight Biotech Stocks Trading Near $5 With Huge Upside Potential

Here are the top biotech stocks to buy that are trading near the $5 dollar level. We have updated coverage…

Jon C. Ogg | Jan 30, 2014 at 8:10 AM EST

Ten Top Wall Street Analyst Stocks to Buy Trading Just Above or Below $5

ThinkstockEvery quarter we like to review the research at the top firms we cover and look for any new stocks…

Jon C. Ogg | Jan 3, 2014 at 8:30 AM EST

Biotech Stocks Under $10 With Huge Upside Potential for 2014

24/7 Wall St. ran a screen of the Wall Street firms we cover looking for biotech stocks trading under $10…

Trey Thoelcke | Dec 27, 2013 at 7:01 AM EST

Ten Top Stocks Trading Under $10 to Buy for Big 2014 Gains

ThinkstockWith less than a week left in what has been the best year for the S&P 500 since 1997, we…

1 2

Galena Biopharma, Inc. : GALE

GALE

$0.26

All GALE Articles

Biostage, Fossil Group Tumble into Friday’s 52-Week Low Club

Gilead Sciences, Fitbit Plunge into Wednesday’s 52-Week Low Club

Wednesday’s Biggest Biopharma Movers

DryShips, Stage Stores Plunge into Monday’s 52-Week Low Club

Galena Rises on FDA Approval

7 Key FDA Decisions and Clinical Trial Results Coming in Q4

4 Companies That Destroyed Shareholders Despite a Brexit Recovery

Is Galena Dead in the Water After This Failed Trial?

8 Major Biopharma Events Coming Later in 2016 and in 2017

Top Wall Street Analyst Sell Ratings on High Profile Stocks This Week

Top Analyst Upgrades and Downgrades: BlackBerry, Care.com, Lululemon, Tesla, Veeco and More

Eight Biotech Stocks Trading Near $5 With Huge Upside Potential

Ten Top Wall Street Analyst Stocks to Buy Trading Just Above or Below $5

Biotech Stocks Under $10 With Huge Upside Potential for 2014

Ten Top Stocks Trading Under $10 to Buy for Big 2014 Gains

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

Galena Biopharma, Inc. : GALE

GALE

$0.26

All GALE Articles

Biostage, Fossil Group Tumble into Friday’s 52-Week Low Club

Gilead Sciences, Fitbit Plunge into Wednesday’s 52-Week Low Club

Wednesday’s Biggest Biopharma Movers

DryShips, Stage Stores Plunge into Monday’s 52-Week Low Club

Galena Rises on FDA Approval

7 Key FDA Decisions and Clinical Trial Results Coming in Q4

4 Companies That Destroyed Shareholders Despite a Brexit Recovery

Is Galena Dead in the Water After This Failed Trial?

8 Major Biopharma Events Coming Later in 2016 and in 2017

Top Wall Street Analyst Sell Ratings on High Profile Stocks This Week

Top Analyst Upgrades and Downgrades: BlackBerry, Care.com, Lululemon, Tesla, Veeco and More

Eight Biotech Stocks Trading Near $5 With Huge Upside Potential

Ten Top Wall Street Analyst Stocks to Buy Trading Just Above or Below $5

Biotech Stocks Under $10 With Huge Upside Potential for 2014

Ten Top Stocks Trading Under $10 to Buy for Big 2014 Gains

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

Featured Reads

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026